278 related articles for article (PubMed ID: 25944801)
1. Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.
Mehta A; Zhang L; Boufraqech M; Liu-Chittenden Y; Zhang Y; Patel D; Davis S; Rosenberg A; Ylaya K; Aufforth R; Li Z; Shen M; Kebebew E
Clin Cancer Res; 2015 Sep; 21(18):4123-32. PubMed ID: 25944801
[TBL] [Abstract][Full Text] [Related]
2. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
3. YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIα at the ATP-Binding Site.
Mackay RP; Weinberger PM; Copland JA; Mahdavian E; Xu Q
Mol Cancer Ther; 2022 Jun; 21(6):925-935. PubMed ID: 35405742
[TBL] [Abstract][Full Text] [Related]
4. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
[TBL] [Abstract][Full Text] [Related]
5. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
9. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
10. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
12. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
[TBL] [Abstract][Full Text] [Related]
13. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
[TBL] [Abstract][Full Text] [Related]
14. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
15. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
16. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
Zhang S; Wang X; Gu Z; Wang L
Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
[TBL] [Abstract][Full Text] [Related]
17. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
[TBL] [Abstract][Full Text] [Related]
18. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
20. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.
Jung SA; Park YM; Hong SW; Moon JH; Shin JS; Lee HR; Ha SH; Lee DH; Kim JH; Kim SM; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Jin DH; Kim T
J Biol Chem; 2015 Apr; 290(16):9974-85. PubMed ID: 25635055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]